Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is in a strong position with its diverse portfolio of regenerative medicine products, including Apligraf and Dermagraft, which have demonstrated the ability to drive more rapid and significant healing in chronic wounds. Despite challenges in the current reimbursement landscape, the company is well positioned to grow in both the advanced wound care and surgical & sports medicine markets, with a potential market opportunity of $31 million for its product ReNu alone. Management has a clear focus on metrics that drive value creation, and the company's strong balance sheet and expected growth in margins make it a compelling investment opportunity for the long term.

Bears say

Organogenesis Holdings is facing multiple headwinds that could negatively impact its financial performance in the near future. These include the recent CMS reimbursement changes, which has led to a significant contraction in the company's end market, and the potential for further disruptions as smaller players exit the market. Additionally, the company's portfolio of regenerative medicine products may face challenges in gaining traction and utilization due to uncertainty around coding, coverage, and commercialization. These factors are likely to result in lower revenue and profitability for Organogenesis Holdings in the short term, with potential upside only expected from its ReNu product, which still faces regulatory and adoption challenges.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.